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PURPOSE. Late-onset central areolar choroidal dystrophy
(CACD) may easily be confused with geographic atrophy (GA)
in AMD. To detect discerning features, the morphologic
changes in CACD patients and in AMD patients were assessed
with confocal scanning laser ophthalmoscopy (cSLO), fundus
autofluorescence (FAF), and spectral-domain optical coher-
ence tomography (SD-OCT).
METHODS. A total of 30 CACD patients with identified PRPH2
gene mutations were analyzed and compared to 19 patients
with early AMD and 13 patients with AMD-associated GA. The
presence of drusen and pigment clumping was determined
with color fundus photography. High-resolution in vivo imag-
ing was performed with cSLO and SD-OCT. FAF images and
SD-OCT volume scans were analyzed in each study eye.
RESULTS. On FAF, a speckled FAF pattern occurred significantly
more often in CACD (85%) than in early AMD (5.6%; P 
0.0001). There was a significantly higher frequency of sub-RPE
deposits in eyes with AMD than in eyes with CACD (36.8%
versus 2.1% of scans, P  0.0019). Reticular drusen could be
visualized by SD-OCT and FAF imaging in 52.6% of the eyes
with early AMD and in 100% of the eyes with GA, whereas this
drusen phenotype did not manifest in eyes with CACD.
CONCLUSIONS. Although outer retinal atrophy is the clinically
common feature in advanced CACD as well as GA, there are
microstructural alterations on high-resolution SD-OCT and FAF
imaging that allow for the differentiation between CACD and
AMD. The findings may help to identify patients in whom a
diagnostic PRPH2 screening is warranted. (ClinicalTrials.gov
number, NCT00393692.) (Invest Ophthalmol Vis Sci. 2011;52:
8908–8918) DOI:10.1167/iovs.11-7926
Central areolar choroidal dystrophy (CACD) is a hereditaryretinal disorder that affects the macula, resulting in pro-
gressive and usually profound visual loss. The hallmark feature
of the disorder is a well-defined atrophy of the retinal pigment
epithelium (RPE) and the choriocapillaris.1 Four clinical stages
of the diseases have been described.2 In stage 1 CACD, subtle
focal parafoveal pigmentary RPE changes can be observed on
ophthalmoscopy. A typical stage 2 finding in the color image is
an oval-to-round, mildly atrophic, hypopigmented area. This
area, on a fundus autofluorescence (FAF) image, shows in-
creased as well as decreased reflectivity resulting in a speckled
FAF pattern. Stage 3 is characterized by one or more patches of
well-demarcated RPE atrophy outside the fovea. In stage 4, the
atrophic area involves the fovea, resulting in a markedly de-
creased visual acuity.2,3
Autosomal dominant CACD is most commonly caused by
mutations in the peripherin-2 (PRPH2) gene (formerly known
as peripherin/RDS).4,5 More than 90 different PRPH2 muta-
tions associated with a wide spectrum of fundus alterations
have been reported. To date, seven different mutations in the
PRPH2 gene have been identified to cause the CACD pheno-
type.6–12 It may be challenging to diagnose CACD in the early
stages of the disorder because of the relative nonspecific RPE
abnormalities. Also, the late-onset variant may easily be con-
fused with age-related macular degeneration (AMD) and thus
be misdiagnosed.
AMD is a complex disease and as such is the result of
multiple factors, some genetic and some exogenous.13 The
early and intermediate stages of AMD are characterized by the
presence of drusen and pigmentary changes. Choroidal neo-
vascularization (CNV) is present in the exudative form while
the advanced nonexudative form (geographic atrophy, GA) is
characterized by atrophy of the retinal pigment epithelium
(RPE), the photoreceptors, and the choriocapillaris. Approxi-
mately 20% of AMD patients with severe visual impairment
have lost central vision due to GA.14–18 Major genetic risk
factors for AMD are certain common variants in the comple-
ment factor H (CFH)19–21 and the age-related maculopathy
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susceptibility 2 (ARMS2/LOC387715) genes.22–24 Subse-
quently, other complement factor genes (i.e., C3, CFB/C2, and
CFI) were found to be associated with AMD.25–28 In contrast,
a study involving 371 cases of AMD showed that the PRPH2
gene appears not to be involved in the pathogenesis of AMD.29
Despite these apparent differences in the underlying patho-
physiological processes, CACD and AMD share many pheno-
typic characteristics. Up to a third of CACD patients develop
visual loss at an older age, showing a considerable overlap with
age of onset in AMD.3 Besides the circumscribed atrophic
lesions that characterize the late stages in both disorders,
drusenlike deposits have been described in a limited number of
patients with CACD.30 In addition, the penetrance of CACD
may be low (up to 21% nonpenetrance), which may mask the
autosomal dominant mode of inheritance in some families and
may further impede the correct diagnosis.3
In the present study, we analyzed the morphologic findings
of 30 genetically confirmed CACD patients and a representa-
tive cohort of patients with early- and late-stage nonexudative
AMD, to detect discerning features on ophthalmoscopy, FAF,
and spectral-domain (SD) optical coherence tomography
(OCT).
PATIENTS AND METHODS
First, we evaluated 60 eyes of 30 patients with genetically proven
CACD in various stages of the disease. All patients with CACD were
randomly chosen from a large CACD cohort and examined at the
Departments of Ophthalmology, Radboud University Nijmegen Medi-
cal Centre (Nijmegen, The Netherlands). Twenty-nine CACD patients
carried the p.Arg142Trp PRPH2 mutation and one patient carried the
p.Arg172Gln PRPH2 mutation. Both mutations were previously asso-
ciated with CACD.6,31 Subsequently, to detect discerning features
between the CACD phonotype and AMD we stratified CACD eyes into
(1) early nonatrophic stages (CACD stages 1 and 2) and (2) late
atrophic stages (CACD stages 3 and 4). Only one eye of each patient
was included into the statistic analysis, resulting in 20 CACD eyes in
group 1 and 18 eyes in group 2.
To compare the CACD phenotype with that of AMD, we evaluated
19 eyes (19 patients) with early AMD and 13 eyes (13 patients) with GA
due to AMD. The diagnosis and grading of AMD was based on an
international classification and grading system for age-related macu-
lopathy and age-related macular degeneration, as described previ-
ously.32 AMD patients were examined at the Department of Ophthal-
mology, University of Bonn, Germany. All patients with AMD were
participants of the multicenter, prospective FAM (Fundus Autofluores-
cence in Age-related Macular Degeneration) study. Eyes with hyper-
pigmentary changes and/or soft drusen without any sign of active or
previous neovascular AMD or GA were included in the study. For
comparison with late CACD stages, eyes with GA due to AMD were
analyzed. These included eyes with FAF patterns similar to the speck-
led CACD FAF pattern in the perilesional zone of GA (i.e., the diffuse
fine granular, the diffuse branching, and the diffuse trickling FAF
phenotype; according to Holz et al. 33) and without signs of active or
previous neovascular AMD. Only one eye of each patient was included
in the analysis, but in cases of bilateral early AMD with bilateral GA,
only the right eye was included.
Genetic Analysis
The 32 AMD patients were analyzed for the presence of the PRPH2
p.Arg142Trp and the p.Arg172Gln mutations by direct Sanger sequenc-
ing. Genomic DNA was isolated from peripheral blood lymphocytes
using standard extraction procedures. The c.424CT (p.Arg142Trp)
and c.515GA (p.Arg172Gln) positions in exon 1 of the PRPH2 gene
were inspected by using the oligonucleotide primers RDS.cEx01-F
(5-CTG CAC TTT TCC CAA GGC CCT AAG TC-3) and RDS.cEx01-R
(5-TGT CCC CAA TAT ATT CAT AGC TCT GAC CC-3) to PCR amplify
the exonic fragment from the patient DNAs. Direct sequencing was
then achieved with primers RDS.cEx01-R, RDS-ex1Fa (5-AGC CAA
GTA TGC CAG ATG GA-3), or RDS-ex1Ra (5-AGC AGA AAG CAG CAG
AGA GC-3) by dye-termination chemistry (Big Dye Terminator Cycle
Sequencing Kit, ver. 1.1; Applied Biosystems, Darmstadt, Germany).
Reactions were analyzed with a sequencer (Prism Model 3130xl; Ap-
plied Biosystems). The study was performed in accordance with the
tenets of the Declaration of Helsinki (1983 revision) and in accordance
with the Medical Research Involving Human Subjects Act (WMO). The
approval of the local ethics committee was obtained for both centers
and a written informed consent to participate in this study was ac-
quired from all subjects.
Image Acquisition and Data Analysis
Pupillary dilatation was achieved with topical 1.0% tropicamide and
2.5% phenylephrine before retinal imaging. Each participant under-
went digital color fundus photography (Imagenet; Topcon Corpora-
tion, Tokyo, Japan [used in Nijmegen]; FF 450 Visupac ZK5; Carl Zeiss
Meditec AG, Jena, Germany [used in Bonn]). High-resolution in vivo
imaging was performed with a combined instrument (Spectralis
HRAOCT, Heidelberg Engineering, Heidelberg, Germany) that allows
for simultaneous recording of SD-OCT and cSLO (confocal scanning
laser ophthalmoscope) as described previously.34 The cSLO images
were obtained according to a standardized operation protocol as de-
scribe before.34,35 Nineteen horizontal SD-OCT scans through the mac-
ula area with simultaneous cSLO imaging were obtained for each study
eye. Individual bands lying below the hyporeflective band of the outer
nuclear layer (ONL) were identified based on recent descriptions, as
depictured in Figure 1.36 Color fundus photography was used to
identify the presence of drusen and pigmentary changes. FAF images
were used to identify CACD stages as described previously.3 In AMD
patients, FAF images were analyzed according to the classification of
FAF patterns in early AMD37 and of abnormal FAF patterns in the
junctional zone of GA, respectively.33
Microstructural changes were analyzed and categorized in consen-
sus meetings of the authors. Subsequently, two graders (DS and MF)
performed qualitative and quantitative analysis on fundus photogra-
phy, FAF and SD-OCT images (19 single SD-OCT scans per study eye).
Quantitative differences in the presence of retinal features were ana-
lyzed using Fisher’s exact test and for the continuous variables, we
used the Mann-Whitney U test. To adjust the P-value for multiple
testing, we performed the Bonferroni correction. Reported P-values
FIGURE 1. SD-OCT scan through the fovea of a normal retina of a
65-year-old male. Different hyperreflective bands can be defined that
appear to correlate with the anatomic layers of the outer retina.36
Layers of the ONL: (1) ELM; (2) IPRL; (3) outer segment–RPE interdig-
itation; and (4) RPE–Bruch’s membrane complex (RPE/BM).
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are two sided and considered statistically significant if lower than 0.002
(all statistical analyses: SPSS, ver. 17.0; IBM SPSS, Chicago, IL).
RESULTS
Description of CACD Stages
Stage 1 CACD. Five eyes of three patients, who were
members of two families, had stage 1 CACD. The presence of
focal parafoveal RPE changes in a predominantly normal retina
characterizes this early stage (Fig. 2). FAF imaging revealed
lipofuscin accumulation indicated by an increased signal of
these parafoveal lesions (Fig 2B). Corresponding SD-OCT scans
showed focal photoreceptor/RPE abnormalities, ranging from
subtle disruption and elongation of the line representing the
interface of the inner and outer segments of the photoreceptor
layer (IPRL) to frank loss of the normal outer retinal anatomy
(Figs. 2C, 2D).
Stage 2 CACD. Stage 2 CACD was diagnosed in 27 eyes of
18 patients received. In this stage, a round and poorly demar-
cated area of hypopigmentation was observed on color fundus
photography (Fig. 3A). The most striking finding was a speck-
led FAF that covered the macula (Fig. 3B). SD-OCT scans of this
area demonstrated a loss of reflectivity and interruption of the
IPRL and, to a lesser extent, of the external limiting membrane
(ELM) (Fig. 3C). In addition, this area showed thinning and
increased irregularity of the ONL. At the central macula, rela-
tive preservation of the reflectivity of the outer photoreceptor
segments was observed (Figs. 3C, 3D). In 11 eyes (40.7%) focal
elongation of the photoreceptor outer segments was present
on the SD-OCT (Fig. 3D). In three eyes (two patients), slight
detachment of the neurosensory retina was noted (Fig. 3E).
Compared to stage 1, a high number of SD-OCT hyperreflective
clumps were noted, generally localized above the level of the
RPE. Approximately 85% of the clumps correlated with mark-
edly increased FAF signals (see Figs. 4D–4F).
Stage 3 CACD. Fourteen eyes of 10 patients demonstrated
well-defined atrophy not involving the macula and were thus
classified with stage 3 CACD (Fig. 4). A typical speckled FAF
pattern always surrounds the atrophic areas (Fig. 4B). As in
stage 2, SD-OCT scans within speckled FAF revealed a reflec-
tivity loss and interruption of IPRL (Fig. 4C). The atrophic
borders were characterized by a relative sharp disruption of
the RPE layer with ELM covering the borders (Figs. 4C, 4F). In
four eyes (29%) rosettelike structures located at the photore-
ceptor layer were observed near the border of the atrophic
area (see Fig. 5D). Hyporeflective spaces, located mainly in the
outer plexiform layer, were occasionally present (39% of stages
3 and 4).
Stage 4 CACD. Fourteen eyes of nine patients demon-
strated central atrophic lesions characteristic for CACD stage 4
(Fig. 5). In areas of atrophy, virtually all outer retinal layers
were absent (Fig. 5C). Rosettelike structures originating from
the photoreceptor layer were observed in 11 (79%) eyes near
the border of the atrophic area (Fig. 5D). Within the atrophic
zones 21% of eyes had clusters of hyperreflective material
correlating with increased FAF.
CACD versus AMD
Patients with CACD were significantly younger than those with
AMD: 53.2 (SD 14.1) years versus 77.1 (SD 7.93) years (P 
0.0001). A positive family history for visual loss was signifi-
cantly more common in CACD than in AMD (80% vs. 9.4%; P
0.0001). None of the AMD patients carried the PRPH2
p.Arg142Trp or the p.Arg172Gln gene mutation. Table 1 pro-
vides an overview of differences between CACD and AMD
patients.
CACD Stages 1 and 2 versus Early AMD. On FAF, a
speckled pattern of increased and decreased FAF signal as
describe before3 occurred significantly more often in CACD
than in AMD (85% vs. 5.6%; P  0.0001). However, the speck-
led FAF pattern in early AMD as described by Bindewald et al.37
(Fig. 6) was not as well demarcated and was more irregularly
shaped than in CACD. In eyes with early AMD, the abnormal
FAF pattern frequently extended beyond the macula and cov-
ered the entire posterior fundus. This effect contrasted with
the sharply demarcated, regularly oval-shaped, speckled FAF
pattern that was usually confined to the central macular in
CACD (Fig. 3 versus Fig. 6). On SD-OCT imaging, in early AMD,
FIGURE 2. Stage 1 CACD. Green line:
positions of the SD-OCT scans. Color
fundus photography (A) showing a para-
foveal increase in reflectivity, with some
pigment clumping, co-locatedwith a dis-
crete increase of FAF (B). (C) Interrup-
tion of the normal anatomy of RPE and
photoreceptor outer segments (arrow).
(D) Subtle disruption, elongation, and
reflectivity loss of IPRL and the RPE–
Bruch’s membrane complex on SD-OCT
(arrow).
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focal accumulations of material under the RPE cell layer were
significantly more often present than in CACD (P  0.0001).
The typical dome-shaped elevations of RPE layer correspond-
ing with soft drusen were visible in 100% of eyes (42.6% of
total scans) in early AMD (Fig. 7) and, elongated sub-RPE
lesions were visible in 65% of eyes (13.4% of total scans) in
early AMD (Fig. 8C). None of the eyes with stage 1 or and 2
CACD showed reticular drusen, whereas 50% of the eyes with
early AMD showed this characteristic finding (P  0.0001; see
Fig. 9D).
CACD Stages 3 and 4 versus GA in AMD. On FAF imag-
ing, among the eyes with GA due to AMD, six eyes showed a
diffuse branching FAF pattern (Fig. 9A); five eyes, a diffuse, fine
granular FAF pattern (Fig. 9B); and two eyes, a diffuse, trickling
(Fig. 9C) FAF pattern in the perilesional zone of atrophy.
Despite the phenotypic resemblance, the FAF changes in AMD
that surround the atrophic lesion were not as well demarcated
from the surrounding retina and often extended beyond the
macular area (Fig. 4B vs. 9A–C). In contrast to AMD, atrophic
lesions in CACD usually showed a sharply demarcated round-
to-oval configuration (Fig. 4). Within SD-OCT scans, there was
a significantly higher frequency of sub-RPE deposits in the
peri-atrophic area in AMD than in eyes with atrophic CACD
(P  0.0001, Table 1). A reticular drusen pattern could be
visualized by SD-OCT and FAF imaging in 92.3% of eyes with
atrophic AMD (Fig. 9D), whereas no eye with CACD showed
this pattern. The atrophic lesions in AMD frequently showed
irregular material remaining on the assumed Bruch’s mem-
brane that gave a more irregular structure (Figs. 9C, 9D) com-
pared with the blank appearance of the remaining retinal layers
in the atrophic lesion in eyes with CACD (Figs. 4, 5).
DISCUSSION
This study was conducted to systematically analyze and com-
pare the morphologic changes in the various stages of AMD
and CACD. In accordance with the ophthalmoscopic similari-
ties of these retinal disorders, SD-OCT and FAF findings also
show that CACD shares many morphologic characteristics with
atrophic AMD. These include hyperpigmentations, abnormal
FAF and occurrence of atrophy of the outer retinal SD-OCT
layers in the advanced stages. Nevertheless, there are morpho-
logic differences that may help in the differentiation between
CACD and AMD (Table 1).
In all but the initial stage of CACD, a speckled FAF pattern
that was sharply demarcated from the surrounding retina, reg-
ularly oval shaped and confined to the central macular, was
observed. In fact, this feature could be considered the hallmark
of CACD stages 2, 3, and 4 and was the most prominent
discriminating characteristic (Fig. 3). Although speckled FAF
patterns previously have been described in AMD,33,37 the al-
terations were less regularly shaped, less well demarcated, and
often extended beyond the macular area. In the speckled FAF
area in CACD, SD-OCT revealed a corresponding disorganiza-
tion of the photoreceptors and a loss of photoreceptor outer
segments, illustrated by a disruption of the inner–outer pho-
toreceptor junction accompanied by a thinning in the ONL.
The predominant photoreceptor loss in CACD is a conse-
quence of the underlying disease process. CACD is caused by
a monogenetic defect in one of the two PRPH2 genes and
potential modifying environmental factors are thought to be of
little relevance in this disorder.3 The Peripherin-2 protein may
function as an adhesion molecule involved in stabilization and
FIGURE 3. Stage 2 CACD. Green
line: the position of the SD-OCT
scans. Color fundus photography (A)
shows a hypopigmented area, co-lo-
cated with a speckled fundus auto-
fluorescence appearance at the mac-
ula (B). SD-OCT shows reflectivity
changes and interruptions of the
IPRL and thinning of the ONL (C).
White arrows (B) indicate the area of
changed SD-OCT between the black
arrows in (C). In CACD stage 2, elon-
gation of the IPRL/RPE is visible in
the transition zone (D, arrow). In
late stage 2 CACD, interruption or
even loss of the IPRL together with
relatively preserved subfoveal reflec-
tivity was noted, suggesting a partial
detachment of the neurosensory ret-
ina (E, arrow).
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compaction of the outer segment discs and/or in the mainte-
nance of the curvature of the rim of the discs.38–40 It has been
demonstrated in a mouse model that one functional PRPH2
allele is unable to support the normal outer segment morpho-
genesis in cones and rods.41 Cones with one functional PRPH2
allele provide better sensitivity to light stimuli than those
completely lacking PRPH2. These cones, however, are not as
efficient in phototransduction as cones in wild-type mice.41 In
FIGURE 4. Stage 3 CACD. Green
line: the position of the SD-OCT
scans. Color fundus photography (A)
shows an atrophy zone co-located
with an absent FAF signal (B, ar-
rows) embedded in a typical speck-
led FAF area. On SD-OCT (C), the
atrophic area shows total absence of
the outer retinal layers (within black
arrows). The outer retinal changes
within the zone of speckled FAF ap-
pears comparable with stage 2 CACD
on SD-OCT. As in stage 2 CACD, hy-
perfluorescent spots on FAF (D,
white arrows) co-localize with hy-
perreflective clumping on SD-OCT
(E, F, black arrow).
FIGURE 5. Stage 4 CACD. Green
line: the position of the SD-OCT
scans. Stage 4 CACD is characterized
by atrophy of the fovea (A). As in
early stages, a typically speckled au-
tofluorescence with outer retinal
changes on SD-OCT can be observed
(B, C, arrows). In tangential SD-OCT
scans through the margin of chori-
oretinal atrophy, rosettelike struc-
tures could be detected in many
cases (D, arrows).
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human CACD patients, there appears to be no detectable early
cone dysfunction, but, as in mice, the disturbance of outer
segment morphogenesis may result in an increased phagocy-
tosis.42–44 The resulting accelerated lipofuscin accumulation in
the RPE may cause progressive impartment of lysosomal func-
tions and,42,45 over time, may contribute to RPE cell death.46
Increased levels of RPE lipofuscin have been measured in a
CACD patient carrying the p.Arg172Trp point mutation.47,48 It
is plausible that the typical speckled FAF in the posterior pole
of CACD stages 2 to 4 represent simultaneous occurrence of
lipofuscin accumulation and focal atrophy of the photorecep-
tor–RPE functional unit. A reduction in cone density within
areas of speckled FAF has also been described in four patients
with macular dystrophies caused by the different PRPH2 mu-
tations.49 Interestingly, in CACD stages 2 and 3, a subfoveal
reflectivity was often preserved, indicating that foveal cones
may be less vulnerable to the effects of a PRPH2 mutation.
Highly heterogeneous FAF patterns in patients with GA in AMD
have been reported previously.49 In this study, we selected and
studied those FAF patterns of AMD-associated GA that could be
confused with speckled FAF pattern as observed in CACD.
Another observation in the CACD group constituted a ro-
settelike structure, mainly located at the border of the atrophic
zone. These were not observed in the AMD group and appear
to represent a morphologic feature associated with CACD.
Rosettelike structures originating from photoreceptors have
been observed in retinas of mice with one functional PRPH2
allele.41 This histopathologic study indicated that the rosettes
develop as a consequence of tensional forces exerted on cells
by the ELM to overcome the excessive space and keep the
photoreceptors close to each other. We hypothesize that our
CACD population resembles this mouse model. However, this
phenomenon is only observed in advanced CACD stages when
the outer segments may lose their normal morphology and RPE
apposition. Zweifel et al.50 described similar structural changes
in the outer retinal layer, also in GA patients, and coined the
term outer retinal tabulations. When we take their study into
consideration, we must conclude that rosettelike structures are
significantly more often present in CACD than in GA.
SD-OCT revealed sub-RPE deposits in eyes with AMD (Figs.
7, 8), whereas these were extremely rare in CACD. We distin-
guished two types of sub-RPE deposits: dome-shaped and elon-
gated sub-RPE deposits. The dome-shaped deposits on SD-OCT
correlated with funduscopically typical soft drusen while the
elongated deposits had no clear funduscopic correlation, but
were frequently associated with hyperpigmentary changes and
a mildly increased FAF signal (Fig. 8). Within the elongated
deposits, in most eyes a characteristic SD-OCT alteration was
subtle splitting of the IPRL, but in eyes of the diffuse-trickling
phenotype, it may be markedly pronounced (Fig. 8).51 The
elongated deposits most likely correlate with basal laminar
deposits (BLamD) histopathologically, which occur between
the RPE basement membrane and the RPE plasma mem-
brane.52–54 BLamD have been identified in human donor eyes
as hallmarks of AMD, particularly in late-stage AMD.54–58 The
higher prevalence of sub-RPE deposits in AMD patients was
also associated with the late atrophic stage. The atrophic zones
in GA were highly irregular and showed residual material on
Bruch’s membrane. In CACD, by contrast, the atrophic areas
were rather smooth and homogeneous. Furthermore, reticular
drusen frequently observed in AMD were never noted adjacent
to or within the CACD lesions. The much higher occurrence of
sub-RPE deposits, the reticular drusen, and the irregular struc-
ture of retinal layers within the atrophic lesion in AMD patients
all indicate different pathogenetic mechanisms for CACD ver-
sus atrophic AMD although, the outer atrophy finally repre-
sents a common downstream pathogenetic pathway. CACD is
a monogenetic disorder that appears to cause direct photore-
ceptor damage with subsequent RPE cell loss. AMD, on the
other hand, is currently thought of as representing a complex,
multifactorial disease characterized by initial (sub)-RPE altera-
tions followed by photoreceptor and RPE cell loss and/or
secondary angiogenic processes.
The prevalence of end-stage AMD has been estimated at
3% in people aged over 65 years, rising to 11% in those over
85 years.59 Therefore, AMD-mimicking diseases should be
suspected in relatively young patients with atrophic lesions.
It seems reasonable to assume that late-onset macular dys-
trophies such as CACD are underdiagnosed and confused
with AMD on a regular basis—the main reasons being the
low prevalence of macular dystrophies and their phenotypic
similarities with AMD, especially in the absence of a positive
FIGURE 6. The speckled FAF pattern in early AMD. This FAF pattern (B) is characterized by the simulta-
neous presence of a variety of FAF abnormalities in a larger area of the FAF image. The changes may extend
beyond the macular area and may cover the entire posterior fundus. Typically, these abnormalities include
multiple small areas of irregularly increased and decreased FAF. The small areas of focal increased FAF may
be punctuate or resemble linear structures. The corresponding abnormalities visible on color fundus
photographs (A) include hyper- and hypopigmentation and multiple subconfluent and confluent drusen.
Reprinted from Bindewald A, Bird AC, Dandekar SS, et al. Classification of fundus autofluorescence
patterns in early age-related macular disease. Invest Ophthalmol Vis Sci. 2005;46(9):3309–3314. ©ARVO.
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FIGURE 7. Subretinal pigment epi-
thelium deposits in early AMD. The
dome-shaped elevations of the outer
retinal layers in the SD-OCT scans
(C–E) correspond to soft drusen on
color fundus photography (A). Hy-
perpigmentations in the fundus im-
age correspond to an increased FAF
signal (B) and hyperreflective struc-
tures overlaying the drusen in the
SD-OCT scan (D). The green line in-
dicates the position of the SD-OCT
scans.
FIGURE 8. Subretinal pigment epi-
thelium deposits in early AMD. Elon-
gated elevations of the outer retinal
layers in the SD-OCT scan (C) may
appear in areas with hyperpigmenta-
tion (A) and mildly increased FAF
(B). Repeated fluorescein angiogra-
phy showed no signs of CNV or scar-
ing (data not shown). Green line: the
position of the SD-OCT scans. In this
eye, there is an extreme amount of
deposit beneath the RPE. In most
AMD eyes, this SD-OCT finding is
more subtle.
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family history. Therapeutic options for both disorders are
currently limited; however, this could change in the near
future. Oxidative stress is involved in AMD pathogenesis,
and antioxidants, such as zinc and certain vitamins, may
slow the progression of the disease.60 In the future, targeted
manipulation of the alternative complement pathway, may
provide a more powerful weapon in the battle against AMD-
related vision loss.61,62 In CACD, the development of gene
therapy, appears currently the most promising approach.
The proper differentiation between AMD and CACD be-
comes of further consequence when the autosomal domi-
nant inheritance of the latter is taken into consideration, as
well as the differences in visual prognosis.
This study identified several morphologic distinguishing
features between CACD and AMD based on noninvasive
novel imaging tools (i.e., SD-OCT and FAF). These findings
may aid the clinician in discerning these entities and may
help in the identification of patients where genetic analysis
for verification of a PRPH2 mutation is warranted.
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